Understanding the Mechanistic Potential of Your Compound

We use commercially available and open-source software to identify the presence of structural alerts in a chemical under evaluation that are positively or negatively associated with an observed activity (e.g., genotoxicity).

At Inotiv, we simplify the integration and interpretation of Tox21 and ToxCast data from quantitative high-throughput screening (qHTS) and high-content (HC) assays using a variety of existing tools and software as well as novel computational workflows developed and applied by our scientists. These workflows are created to account for your program’s unique needs as well as the continual updating of source data, ensuring flexibility and relevance. Our expertise makes this complex work approachable and understandable, enabling our clients to leverage such large data sources effectively and with confidence.

Inotiv's staff helps you maximize the information gained from in vitro data. Our scientists leverage domain expertise to characterize an assay’s mechanism of action and possible adverse outcome pathway targets. Using this information, in vitro to in vivo extrapolation (IVIVE) models provide data that are useful in your dose selection and estimation of toxicity reference/screening values. Our staff is experienced in conducting IVIVE, including reverse toxicokinetic modeling and physiological-based pharmacokinetic (PBPK) models. We utilize PBPK modelling to help predict pharmacokinetics and pharmacodynamics from drug administration or chemical exposure in humans from rodent or in vitro experiments. Using these models, we examine the effects of age, gender, disease state, population variability, and/or drug-drug interactions/chemical mixtures on exposures.